Libra Infusions made profits in three quarters of FY22

Libra Infusions Limited has released its quarterly financial statements for the period July-March of FY22, as the company recorded impressive profit growth compared to the previous financial year.

According to Sunday’s stock market disclosure, in FY22 between July and March, its earnings per share stood at Tk 4, a loss of Tk 6.44 during the same period of the financial year. previous.

In the January-March quarter, its earnings per share stood at Tk1.37, a loss of Tk5.69 in the same period of the previous financial year.

In the October-December quarter, its earnings per share stood at Tk1.78, a loss of Tk1.48 in the same period of the previous fiscal year.

During July-September, its earnings per share stood at Tk 0.85, compared to Tk 0.71 in the same period of the previous financial year.

At the end of March 2022, its net asset value per share was Tk843.

Investors were left in the dark because the company failed to release its financial information in a timely and complete manner. As a result, they were unable to make informed decisions regarding their investments in the company.

In August, its share price was Tk 674, which reached Tk 1,063.8 in 14 working days. After September, it also fell to Tk744 amid political and economic uncertainty.

On Sunday, the company’s share price stood at Tk 957.5 at the Dhaka Stock Exchange.

Market insiders say the country’s largest saline producer, Libra Infusions, currently has a paid-up capital of only Tk 2.25 crore, while the regulatory requirement is Tk 30 crore.

The Securities and Exchange Commission of Bangladesh had earlier asked the company to increase its paid-up capital to meet the regulatory standard.

Additionally, the company is set to launch the country’s largest dialysis fluid production plant, which could significantly improve its profitability. Market insiders also said the company may take steps to increase its paid-up capital, with an announcement expected in the coming days.